Johnson & Johnson (JNJ)
This Super-Safe High-Yield Stock Just Extended Its Dividend Growth Streak to 63 Years in a Row
Johnson & Johnson (JNJ 0.22%) continues to treat its investors like royalty. The healthcare behemoth recently gave them another raise, increasing its dividend payment by 4.8%.
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
On the one hand, the company beat on the top and bottom lines and offered better-than-expected guidance. On the other hand, JNJ acknowledged the likelihood of a $400 million tariff hit on the company's medical device business that will impact business in the short term.
J&J's Spravato momentum points to commercial viability of psychedelics for mental health, analysts say
Another quarter of consistent growth for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato bodes well for other psychedelics, analysts at Jefferies believe. They see consistent quarter-over-quarter Spravato sales growth supporting the notion psychedelics can become commercially viable in mental health.
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer John Reed - EVP, Innovative Medicine, R&D Joseph Wolk - EVP, Chief Financial Officer Jennifer Taubert - EVP, Worldwide Chairman, Innovative Medicine Tim Schmid - EVP, Worldwide Chairman, MedTech Conference Call Participants Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Asad Haider - Goldman Sachs Danielle Antalffy - UBS Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Matt Miksic - Barclays Tim Anderson - Bank of America Operator Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference.
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and increased its dividend, reflecting confidence in long-term growth despite short-term litigation and tariff uncertainties.
Compared to Estimates, Johnson & Johnson (JNJ) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex. Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.
Johnson & Johnson raised its sales outlook, even with tariff costs included
Johnson & Johnson beat Wall Street's expectations for first-quarter profit and revenue on Tuesday, as strong growth in the U.S. offset weakness internationally.
Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
J&J Increases Outlook After Beating 1Q Expectations
Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.
